Sanofi-Aventis Sues Over Eloxatin Ingredient

By Amanda Ernst

Law360, New York (May 02, 2008, 12:00 AM ET) -- Sanofi-Aventis has filed suit against W.C. Heraeus GmbH, claiming the German precious metals company is aiding infringement of a patent for Sanofi’s colon cancer drug Eloxatin by providing an important active pharmaceutical ingredient to three generics makers.

The suit against Heraeus is the 15th that Sanofi has filed in the U.S. District Court for the District of New Jersey in an effort to prevent pharmaceutical companies from marketing generic versions of oxaliplatin, the active ingredient in Eloxatin.

In its most recent complaint, the French pharmaceutical company,...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles